MHRA publishes final Business Plan for 2023-2026 Corporate Plan
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives innovation; being a great place to work and providing excellent customer service.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its Business Plan for 2025/26, reaffirming its commitment to keeping patients safe and enabling access to high quality and effective medical products through innovation across the UK.
As an Executive Agency of the Department of Health and Social Care, the MHRA plays a key role in delivering the Government’s priorities to help people live healthier, longer lives. This includes supporting the missions to ensure safe and fast regulatory approval, helping build an NHS fit for the future, and driving innovation and growth in the UK’s Life Sciences sector.
The MHRA Business Plan for 2025/26 includes commitments towards:
-
Strengthening patient safety further, by making safety monitoring faster, more efficient, and more data driven
-
Implementing an agile and risk-proportionate regulatory environment that enables growth
-
Embedding changes needed to continue maintaining consistent performance and efficient delivery of core services within predictable timeframes.
The full MHRA Business Plan 2025/26 can be found on the MHRA website.
Notes to Editors
-
The MHRA’s 2025/26 Business Plan is available here.
-
The MHRA is an executive agency of the Department of Health and Social Care.
-
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates all medicines and medical devices in the UK, ensuring they are effective and acceptably safe. All decisions are underpinned by rigorous, evidence-based judgements to ensure the benefits outweigh any risks.
-
For media enquiries, please contact: newscentre@mhra.gov.uk or call 020 3080 7651.